Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

9

Revenue 2017

Gilead Sciences

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Gilead Sciences' 2013 sales performance.

Gilead Sciences, Inc.

HTA guidance from NICE, the SMC and the AWMSG

Here we present a feed of upcoming health technology assessment (HTA) decisions, covering appraisals by the National Institute of Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC) and the All Wales Medicines Strategy Group

EMA begins accelerated review of Gilead’s Trodelvy for triple-negative breast cancer

EMA begins accelerated review of Gilead’s Trodelvy for triple-negative breast cancer The European Medicines Agency (EMA) has begun an accelerated review of Gilead’s Trodelvy for the treatment of advanced triple-negative breast cancer. ... Gilead is also testing Trodelvy’s potential in non-small cell lung cancer and metastatic

Setting up for success in a post-Brexit, post-pandemic Britain

Setting up for success in a post-Brexit, post-pandemic Britain and running, ahead of our UK marketing authorisation in IBD, through our partnership with Gilead. ... With a focus on inflammatory and fibrotic conditions, we have submitted a marketing application through our partnership with Gilead for a new treatment

Gilead and Novo Nordisk boost NASH partnership with new mid-stage study

Gilead and Novo Nordisk boost NASH partnership with new mid-stage study The two companies first announced their NASH collaboration in 2019. Gilead and Novo Nordisk have planned a new phase 2b trial in a bid to expand their clinical collaboration in ... The two companies first announced their collaboration in 2019, focused on

Yescarta gains first FDA approval for indolent follicular lymphoma

Yescarta gains first FDA approval for indolent follicular lymphoma First CAR-T cell therapy to be approved in this indication. Gilead subsidiary Kite's Yescarta has been granted accelerated approval from the US Food and Drug Administration (FDA) for indolent

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....